Asia Ex-Japan Funds: Extreme stocks
In this report, Steven Holden screens for stocks at the extreme ends of their positioning or momentum ranges. He synthesises current and historical data on fund positioning with recent manager activity to accurately assess sentiment for each stock within Copley’s coverage. Stocks highlighted include Phoenix Mills and SK Hynix (High Positioning, Positive Momentum); AIA Group and Shenzhen Inovance Technology Co. (High Positioning, Negative Momentum); PT Avia Avian and Wuxi Biologics (Low Positioning, Negative Momentum); New Oriental Education & Technology Group and Shinhan Financial Group (Low Positioning, Positive Momentum).
Edition: 192
- 09 August, 2024
Healthcare
Biologics key play on Pharma moving to ‘Fabless’ outsourced manufacturing model - an increasing number of Biotech / Pharma companies are choosing to outsource production facilities to avoid navigating the increasingly challenging regulatory landscape on their own. By combining a CRO and CDMO business model, the result is a full-scale CRDMO providing a completely integrated suite of end-to-end pharma solutions, WuXi (and Samsung Biologics) are both in this elite category. At the end of 2021, WuXi had already secured 60 integrated projects from customers worldwide (+50% y/y). The recent share price sell-off on US sanction fears is overdone.
Edition: 132
- 01 April, 2022